COLL - COLLEGIUM PHARMACEUTICAL, INC
IEX Last Trade
29.11
-9.650 -33.150%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:59 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$38.76
-9.65
-24.90%
Fundamental analysis
74%
Profitability
76%
Dept financing
48%
Liquidity
74%
Performance
77%
Performance
5 Days
-2.15%
1 Month
-5.62%
3 Months
-22.30%
6 Months
-7.78%
1 Year
-3.29%
2 Year
26.57%
Key data
Stock price
$29.11
DAY RANGE
$28.99 - $38.76
52 WEEK RANGE
$29.26 - $42.29
52 WEEK CHANGE
-$5.59
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Joseph J. Ciaffoni
Region: US
Website: collegiumpharma.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: collegiumpharma.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Collegium Pharmaceutical, Inc. develops and commercializes medicines for pain management. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone.
Recent news